21 January 2026
ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate
ErVimmune, a biotechnology company developing next-generation therapeutic vaccines targeting new families of ‘unconventional’ tumor antigens derived from human endogenous...